Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test

Key Points

• Inventiva expects top-line results in Q4 2026 from its fully enrolled Phase III NATiV3 trial of lanifibranor in more than 1,000 MASH patients; the final patient visit has been completed.
• The company is seeking to replicate its Phase IIb findings, which included placebo-adjusted improvements in fibrosis, MASH resolution and a composite endpoint. Patients with F3 fibrosis and diabetes could represent an initial treatment population if the drug is approved.
• Inventiva is preparing for potential independent commercialization and says its cash runway extends through Q2 2027, potentially into early 2028 with additional financing if Phase III results are positive.

Inventiva NASDAQ: IVA said it expects to report top-line results in the fourth quarter of 2026 from its fully enrolled Phase III NATiV3 trial of lanifibranor in patients with metabolic dysfunction-associated steatohepatitis, or MASH.

Chief Executive Officer Andrew Obenshain said the final patient visit in NATiV3 has been completed. The study includes more than 1,000 patients and was designed to resemble the company’s earlier Phase IIb NATIVE trial, while using a longer duration and a larger patient population.

“When I look at the opportunity we see in lanifibranor, it really comes down to three things: differentiation, late-stage validation, and market opportunity,” Obenshain said.

Phase II Results and Phase III Design

In the Phase IIb study, Inventiva reported an 18% placebo-adjusted improvement in fibrosis, a 26% rate of MASH resolution, and a 24% result on a composite endpoint after six months, according to Obenshain. The company is seeking to replicate the Phase II findings in NATiV3 rather than requiring a larger treatment effect to support its commercial expectations.

Chief Medical Officer Jason Campagna said NATiV3’s population is broadly similar to the earlier study, although it includes more patients with F3 fibrosis and diabetes. He said the company used conservative assumptions in powering the trial, including a higher projected placebo response and lower assumed drug effect than those observed in Phase II, while also over-enrolling to account for potential patient discontinuations.

Campagna said Inventiva views patients with F3 fibrosis and diabetes as a potential initial treatment segment if lanifibranor is approved. He said the company believes treatment use could expand into other patient groups depending on the efficacy profile observed in Phase III.

PPAR Mechanism and Safety Considerations

Lanifibranor is designed as a balanced agonist of all three peroxisome proliferator-activated receptor, or PPAR, isoforms: alpha, delta and gamma. Campagna said the drug was designed to provide activity across inflammatory, metabolic and fibrotic pathways while acting as only a partial agonist at PPAR gamma.

According to Campagna, the partial PPAR-gamma activity is intended to reduce certain tolerability concerns historically associated with some PPAR agents, including fluid retention, peripheral edema, weight gain and dilutional anemia. He said the company does not expect those effects to be eliminated, but believes they should be moderated compared with traditional full PPAR-gamma agonists such as pioglitazone.

Campagna also discussed biomarker results from earlier studies. He said lanifibranor increased adiponectin by roughly threefold to fivefold depending on dose, reduced hemoglobin A1c by approximately 0.5% to 0.7%, and lowered triglycerides by about 30%. In the company’s LEGEND trial, he said a combination with an SGLT2 inhibitor approached a 1.2% reduction in A1c.

On noninvasive liver measurements, Campagna said many serum and imaging biomarkers tracked with histology, including PRO-C3, transaminases and components of the ELF test. He acknowledged that FibroScan liver stiffness results appeared less pronounced relative to histological findings, with about a 10% reduction after six months. He attributed that partly to fluid retention, which can affect liver-stiffness measurements.

Commercial Plans and Financial Runway

Obenshain said Inventiva is building the organization with the intention of commercializing lanifibranor independently if the study is successful. The company recently named Chris Benecchi as chief operating officer, which Obenshain said reflects its preparation for a potential launch.

He added that the company continues to see pharmaceutical industry interest in metabolic disease and MASH, though Inventiva is currently planning around an independent commercialization strategy. Obenshain said a potential acquisition remains possible but is not the basis for the company’s operating plans.

Chief Financial Officer Axel-Sven Malkomes said Inventiva’s current cash runway extends through the end of the second quarter of 2027. If Phase III data are positive and the company can access additional refinancing tranches, he said the runway could extend to the beginning of 2028, covering the anticipated data readout and a potential new drug application filing.

Potential Expansion Areas

Inventiva is also considering opportunities in later-stage MASH populations, including patients with late F3 fibrosis or compensated F4 disease who have clinically significant portal hypertension. Campagna referred to this group as “CACKLED,” describing patients at elevated risk for liver-related outcomes.

He said the company has data it believes could support further investigation of lanifibranor in that population after the NATiV3 top-line readout. Campagna also said Inventiva is interested in the overlap between MASH-related metabolic drivers and heart failure with preserved ejection fraction, while noting that treatment decisions involving PPAR therapies require patient-specific considerations.

About Inventiva (NASDAQ:IVA)

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Dijon, France. The company develops oral small-molecule therapies for chronic metabolic and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva's lead product candidate is lanifibranor, an investigational pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.